scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1018375817 |
P356 | DOI | 10.1007/S11894-012-0265-5 |
P698 | PubMed publication ID | 22581276 |
P2093 | author name string | John Betteridge | |
Patrick E Young | |||
Ganesh R Veerappan | |||
P2860 | cites work | Development of the human infant intestinal microbiota | Q21003936 |
Inflammatory Bowel Disease | Q22248115 | ||
Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis | Q22251072 | ||
A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease | Q22251291 | ||
Probiotics for maintenance of remission in ulcerative colitis | Q24234400 | ||
Interventions for prevention of post-operative recurrence of Crohn's disease | Q24240542 | ||
Probiotics for induction of remission in Crohn's disease | Q24242115 | ||
Probiotics for induction of remission in ulcerative colitis | Q24242963 | ||
Probiotics for maintenance of remission in Crohn's disease | Q24244110 | ||
Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice | Q24523182 | ||
Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine | Q24685766 | ||
Lactobacillus GG in inducing and maintaining remission of Crohn's disease | Q24806098 | ||
Saccharomyces boulardii in maintenance treatment of Crohn's disease | Q28144634 | ||
A pilot trial of Saccharomyces boulardii in ulcerative colitis | Q28184581 | ||
Gut flora in health and disease | Q28209082 | ||
The host-microbe interface within the gut | Q28216971 | ||
Probiotic use in clinical practice: what are the risks? | Q28245049 | ||
Unravelling the pathogenesis of inflammatory bowel disease | Q29547551 | ||
New concepts in the pathophysiology of inflammatory bowel disease | Q30438997 | ||
Assessment of Mucosal Inflammation and Circulation in Response to Probiotics in Patients Operated with Ileal Pouch Anal Anastomosis for Ulcerative Colitis | Q30927782 | ||
Assessment of mucosal inflammation and blood flow in response to four weeks' intervention with probiotics in patients operated with a J-configurated ileal-pouch-anal-anastomosis (IPAA). | Q33212468 | ||
Potential probiotic characteristics of Lactobacillus and Enterococcus strains isolated from traditional dadih fermented milk against pathogen intestinal colonization | Q33280100 | ||
Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN) | Q33557634 | ||
Colitis in transgenic and knockout animals as models of human inflammatory bowel disease | Q33713331 | ||
Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial | Q33872486 | ||
Gut microbial diversity is reduced by the probiotic VSL#3 and correlates with decreased TNBS-induced colitis | Q34192292 | ||
Pouchitis: result of microbial imbalance? | Q34378691 | ||
Complementary and alternative medicine use by patients with inflammatory bowel disease: results from a postal survey | Q34499357 | ||
Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial | Q34510060 | ||
Role of the faecal stream in the maintenance of Crohn's colitis | Q34526492 | ||
Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG. | Q34547390 | ||
A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease | Q34560319 | ||
A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease | Q34588311 | ||
Recommendations for probiotic use-2011 update | Q34632974 | ||
Probiotics, nuclear receptor signaling, and anti-inflammatory pathways | Q35131051 | ||
Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. | Q35233808 | ||
Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. | Q35594940 | ||
Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis | Q35596222 | ||
Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon | Q35598397 | ||
Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. | Q35760489 | ||
The bacteriology of pouchitis: a molecular phylogenetic analysis using 16S rRNA gene cloning and sequencing | Q35799373 | ||
Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens | Q35890738 | ||
The role of enteric microflora in inflammatory bowel disease: human and animal studies with probiotics and prebiotics. | Q36220431 | ||
Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice | Q36273531 | ||
Production of experimental ulcerative colitis in gnotobiotic guinea pigs with simplified microflora | Q36422699 | ||
Clinical efficacy of probiotics: review of the evidence with focus on children | Q36620391 | ||
Bacteria- and host-derived mechanisms to control intestinal epithelial cell homeostasis: implications for chronic inflammation | Q36809889 | ||
Probiotics and remission of ulcerative colitis: a systematic review | Q37031840 | ||
Mechanisms of probiotic action: Implications for therapeutic applications in inflammatory bowel diseases | Q37214848 | ||
Probiotics in the treatment of human inflammatory bowel diseases: update 2011. | Q37944981 | ||
Prebiotics and probiotics: their role in the management of gastrointestinal disorders in adults | Q37962875 | ||
Real-time PCR quantification of bacterial adhesion to Caco-2 cells: competition between bifidobacteria and enteropathogens | Q40396945 | ||
Effects of the faecal stream and stasis on the ileal pouch mucosa | Q41813315 | ||
Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro | Q42282244 | ||
Antibiotics and probiotics in chronic pouchitis: a comparative proteomic approach. | Q42945261 | ||
Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial | Q43363077 | ||
Mucosal flora in inflammatory bowel disease | Q43503928 | ||
Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. | Q45126890 | ||
Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis | Q45166043 | ||
Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis | Q46143449 | ||
Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells | Q47945739 | ||
Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: a pilot study | Q48677169 | ||
High dose probiotic and prebiotic cotherapy for remission induction of active Crohn's disease. | Q53231256 | ||
Failure of Synbiotic 2000 to prevent postoperative recurrence of Crohn's disease | Q57124109 | ||
Role of commercial probiotic strains against human pathogen adhesion to intestinal mucus | Q58261045 | ||
VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis | Q59120549 | ||
Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles | Q59880418 | ||
Is Lactobacillus GG Helpful in Children With Crohn’s Disease? Results of a Preliminary, Open-Label Study | Q63285887 | ||
Pouchitis following ileal pouch-anal anastomosis: definition, pathogenesis, and treatment | Q72800631 | ||
Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora | Q73092300 | ||
Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis | Q73837821 | ||
Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? | Q74126152 | ||
Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum | Q74133428 | ||
Inflammatory bowel disease: lessons from the IL-10 gene-deficient mouse | Q74625172 | ||
Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after lleo-caecal resection | Q79502910 | ||
Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis | Q83333118 | ||
The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis | Q84290217 | ||
P433 | issue | 4 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | inflammation | Q101991 |
inflammatory bowel diseases | Q917447 | ||
probiotics | Q1816730 | ||
P304 | page(s) | 324-333 | |
P577 | publication date | 2012-08-01 | |
P1433 | published in | Current gastroenterology reports | Q26842032 |
P1476 | title | Probiotics for the treatment of inflammatory bowel disease | |
P478 | volume | 14 |
Q37680765 | A phase one safety study of Lactobacillus reuteri conducted in the Peruvian Amazon: Observations from the field |
Q41816719 | Actions of probiotics on trinitrobenzenesulfonic acid-induced colitis in rats |
Q35688499 | Attenuation of Colitis by Lactobacillus casei BL23 Is Dependent on the Dairy Delivery Matrix |
Q35134825 | Beneficial modulation of the gut microbiota. |
Q57825805 | Biological Activities of Lactose-Derived Prebiotics and Symbiotic with Probiotics on Gastrointestinal System |
Q28817192 | Can probiotics modulate human disease by impacting intestinal barrier function? |
Q26768564 | Diet therapy for inflammatory bowel diseases: The established and the new |
Q27330156 | Disturbance in the Mucosa-Associated Commensal Bacteria Is Associated with the Exacerbation of Chronic Colitis by Repeated Psychological Stress; Is That the New Target of Probiotics? |
Q39249472 | Efficacy of Bifidobacterium breve NCC2950 against DSS-induced colitis is dependent on bacterial preparation and timing of administration |
Q36830824 | Enteropathic spondyloarthritis: from diagnosis to treatment. |
Q34716086 | Environment-related adaptive changes of gut commensal microbiota do not alter colonic toll-like receptors but modulate the local expression of sensory-related systems in rats. |
Q26783044 | Gut Function-Enhancing Properties and Metabolic Effects of Dietary Indigestible Sugars in Rodents and Rabbits |
Q26995672 | Gut microbial flora, prebiotics, and probiotics in IBD: their current usage and utility |
Q33801736 | Gut microbiome composition and function in experimental colitis during active disease and treatment-induced remission |
Q34549031 | Gut microbiota, inflammation and colorectal cancer |
Q28551430 | Highly Heterogeneous Probiotic Lactobacillus Species in Healthy Iranians with Low Functional Activities |
Q34168490 | Infectious etiopathogenesis of Crohn's disease |
Q52564079 | Inflammatory Bowel Disease and Immunonutrition: Novel Therapeutic Approaches Through Modulation of Diet and the Gut Microbiome. |
Q64912397 | Intestinal Microbiome, Small Intestinal Bacterial Overgrowth and Inflammatory Bowel Diseases - What are the Connections? |
Q35245299 | Intestinal microbiota, probiotics and prebiotics in inflammatory bowel disease |
Q35018358 | Lactobacillus acidophilus alleviates platelet-activating factor-induced inflammatory responses in human intestinal epithelial cells |
Q38130307 | Microbial activation of gut dendritic cells and the control of mucosal immunity |
Q35195891 | Modulating the microbiota in inflammatory bowel diseases: prebiotics, probiotics or faecal transplantation? |
Q41313491 | Modulation of Gut Microbiome Composition and Function in Experimental Colitis Treated with Sulfasalazine |
Q26772345 | Nutritional Keys for Intestinal Barrier Modulation |
Q42216604 | Practical approaches to probiotics use. |
Q29037475 | Probiotic Mix VSL#3 Is Effective Adjunctive Therapy for Mild to Moderately Active Ulcerative Colitis |
Q44399817 | Probiotic therapy reduces periodontal tissue destruction and improves the intestinal morphology in rats with ligature-induced periodontitis |
Q28087443 | Probiotics, prebiotics and synbiotics- a review |
Q53542322 | Role of Faecalibacterium prausnitzii in Crohn's Disease: friend, foe, or does not really matter? |
Q34407175 | Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years? |
Q28254207 | Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease |
Q60959001 | The Dietary Intervention of Transgenic Low-Gliadin Wheat Bread in Patients with Non-Celiac Gluten Sensitivity (NCGS) Showed No Differences with Gluten Free Diet (GFD) but Provides Better Gut Microbiota Profile |
Q35156014 | The multifaceted role of commensal microbiota in homeostasis and gastrointestinal diseases |
Q35770445 | What colorectal surgeons should know about probiotics: a review |
Search more.